Expanded human tissue kallikrein family - A novel panel of cancer biomarkers

Tumor Biology

Volumn 23, Issue 3, 2002, Pages 185-192

  Yousef, George M ^b   Diamandis, Eleftherios P ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b NONE

Author keywords

Breast cancer; Cancer prognosis; Kallikrein; Ovarian cancer; Prostate cancer; Prostate specific antigen; Testicular cancer; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; GROWTH FACTOR; HORMONE; HUMAN GLANDULAR KALLIKREIN 2; KALLIKREIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN HK10; PROTEIN HK11; PROTEIN HK2; PROTEIN HK3; PROTEIN HK6; TISSUE KALLIKREIN; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CHROMOSOME 19Q; DRUG TARGETING; ENDOCRINE DISEASE; EXTRACELLULAR MATRIX; FOLLOW UP; GENE; GENE EXPRESSION; GENE LOCUS; HK10 GENE; HK11 GENE; HK3 GENE; HK6 GENE; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; METASTASIS; MULTIGENE FAMILY; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; TESTIS CANCER; CHEMISTRY; GENETICS; NEOPLASM; PROGNOSIS;

HUMANS; NEOPLASMS; PROGNOSIS; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036562226     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064027     Document Type: Review

References (56)

1. Beaubien G, Rosinski-Chupin I, Mattei MG, Mbikay M, Chretien M, Seidah NG: Gene structure and chromosomal localization of plasma kallikrein. Biochemistry 1991;30:1628-1635.
2. Yousef GM, Chang A, Scorilas A, Diamandis EP: Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000;276:125-133.
3. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP: Cloning of a new member of the human kallikrein gene family. KLK14, which is down-regulated in different malignancies. Cancer Res 2001;61:3425-3431.
4. Foussias G, Yousef GM, Diamandis EP: Identification and molecular characterization of a novel member of the siglec family (SIGLEC9). Genomics 2000;67:171-178.
5. Yousef GM, Ordon M, Foussias G, Diamandis EP: Genomic organization of the Siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes. Gene 2002;286:259-270.
6. Yousef GM, Diamandis M, Jung K, Diamandis EP: Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. Genomics 2001;74:385-395.
7. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 2001;22:184-204.
8. Yousef GM, Diamandis EP: Human kallikreins: Common structural features, sequence analysis and evolution. Curr Genomics, in press.
9. Diamandis EP, Yousef GM, Clements J, et al: New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000;46:1855-1858.
10. Yousef GM, Kyriakopoulou LG, Scorilas A, et al: Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: A new independent and favorable prognostic marker. Cancer Res 2001;61:7811-7818.
11. Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP: Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 2001;276:53-61.
12. Yousef GM, Chang A, Diamandis EP: Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 2000;275:11891-11898.
13. Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP: The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - genomic characterization, mapping, tissue expression and hormonal regulation. Gene 2000;254:119-128.
14. Yousef GM, Scorilas A, Diamandis EP: Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics 2000;63:88-96.
15. Rittennouse HG, Finlay JA, Mikolajczyk SD, Partin AW: Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
16. Yu H, Giai M, Diamandis EP, et al: Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995;55:2104-110.
17. Black MH, Diamandis EP: The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 2000;59:1-14.
18. Anisowicz A, Sotivopoulou G, Stenman G, Mok SC, Sager R: A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996;2:624-636.
19. Liu XL, Wazer DE, Watanabe K, Band V: Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996;56:3371-3379.
20. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V: The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998;58:4782-4786.
21. Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ: Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 1999;59:4435-4439.
22. Magklara A, Scorilas A, Katsaros D, et al: The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001;7:806-811.
23. Tanimoto H, Underwood LJ, Shigemasa K, et al: The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999;86:2074-2082.
24. Obiezu CV, Scorilas A, Katsaros D, et al: Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 2001;7:2380-6.
25. Kim H, Scorilas A, Katsaros D, et al: Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 2001;84:643-650.
26. Dong Y, Kaushal A, Bui L, et al: Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 2001;7:2363-2371.
27. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P: Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 2000;33:579-583.
28. Diamandis EP, Yousef GM, Soosaipillai AR, et al: Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 2000;33:369-375.
29. Luo LY, Katsaros D, Scorilas A, et al: Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 2001;7:2372-2379.
30. Luo L, Bunting P, Scorilas A, Diamandis EP: Human kallikrein 10: A novel tumor marker for ovarian carcinoma? Clin Chim Acta 2001;306:111-118.
31. Diamandis EP, Okui A, Mitsui S, et al: Human kallikrein 11: A new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295-300.
32. Wolf WC, Evans DM, Chao L, Chao J: A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol 2001;159:1797-1805.
33. Nelson PS, Gan L, Ferguson C, et al: Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999;96:3114-3119.
34. Hooper JD, Bui LT, Rae FK, et al: Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 2001;73:117-122.
35. Yousef GM, Scorilas A, Diamandis EP: Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics 2000;63:88-96.
36. Yousef GM, Magklara A, Diamandis EP: KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 2000;69:331-341.
37. Sappino AP, Busso N, Belin D, Vassalli JD: Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987;47:4043-4046.
38. Takayama TK, Fujikawa K, Davie EW: Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997;272:21582-21588.
39. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K: Characterization of hK4 (prostase), a prostate-specific serine protease: Activation of the precursor of prostate-specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001;40:15341-15348.
40. Smyth MJ: Starum corneum chymotryptic enzyme; in Barrett AJ, Rawlings NP, Woessner JF (eds): Handbook of Proteolytic Enzymes. London, Academic Press, 1998, pp 87-89.
41. Sutkowski DM, Goode RL, Baniel J, et al: Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999;91:1663-1669.
42. Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S: Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996;48:317-325.
43. Matsui H, Takahashi T: Mouse testicular Leydig cells express KLK21, a tissue kallikrein that cleaves fibronectin and IGF-binding protein-3, Endocrinology 2001;142:4918-4929.
44. Fortier AH, Nelson BJ, Grella DK, Holaday JW: Antiangiogenic activity of prostate-specific antigen. J Natl Cancer 1999;91:1635-1640.
45. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R: Proteinase-activated receptors. Pharmacol Rev 2001;53:245-282.
46. Bhoola K, Ramsaroop R, Plendl J, Cassim B, Dlamini Z, Naicker S: Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 2001;382:77-89.
47. Tanimolo H, Underwood LJ, Shigemasa K, Parmley TH, O'Brien TJ: Increased expression of protease M in ovarian tumors. Tumour Biol 2001;22:11-18.
48. Yousef GM, Scorilas A, Kyriakopoulou LG, et al: Human kallikrein gene 5 (KLK5) expression by quantitative PCR: An independent indicator of poor prognosis in breast cancer. Clin Chem, in press.
49. Dhar S, Bhargava R, Yunes M, et al: Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res 2001;7:3393-3398.
50. Chang A, Yousef GM, Scorilas A, et al: Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: An independent indicator of favorable prognosis in breast cancer. Br J Cancer 2002;86:1457-1464.
51. Partin AW, Catalona WJ, Finlay JA, et al: Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis. Urology 1999;54:839-845.
52. Diamandis EP: Prostate-specific antigen - its usefulness in clinical medicine. Trends Endocrinol Metab 1998;9:310-316.
53. Yousef GM, Scorilas A, Chang A, et al: Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 2002;86:1457-1464.
54. Yousef GM, Obiezu C, Jung K, Stephan C, Scorilas A, Diamandis EP: Differential expression of kallikrein gene 5 (KLK5) in cancerous and normal testicular tissues. Urology, in press.
55. Luo LY, Rajpert-De Meyts ER, Jung K, Diamandis EP: Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 2001;85:220-224.
56. Luo L-Y, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA: Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer, in press.